Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

The incorporation of circulating tumor DNA (ctDNA) into the management of operable breast cancer (BC) has been hampered by the heterogeneous results from different studies. We aimed to assess the prognostic value of ctDNA in patients with operable (non metastatic) BC.

Materials and methods

A systematic search of databases (PubMed/Medline, Embase, and CENTRAL) and conference proceedings was conducted to identify studies reporting the association of ctDNA detection with disease-free survival (DFS) and overall survival (OS) in patients with stage I-III BC. Log-hazard ratios (HRs) were pooled at each timepoint of ctDNA assessment (baseline, after neoadjuvant therapy, and follow-up). ctDNA assays were classified as primary tumor-informed and non tumor-informed.

Resu

SUBMITTER: Nader-Marta G 

PROVIDER: S-EPMC10940943 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature